BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15834298)

  • 21. Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER-Verapamil Study Group.
    White WB; Mehrotra DV; Black HR; Fakouhi TD
    Am J Cardiol; 1997 Aug; 80(4):469-74. PubMed ID: 9285660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
    Frishman WH; Glasser S; Stone P; Deedwania PC; Johnson M; Fakouhi TD
    Am J Cardiol; 1999 Feb; 83(4):507-14. PubMed ID: 10073852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning.
    Neutel JM; Alderman M; Anders RJ; Weber MA
    Am Heart J; 1996 Dec; 132(6):1202-6. PubMed ID: 8969572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product.
    White WB; Black HR; Weber MA; Elliott WJ; Bryzinski B; Fakouhi TD
    Am J Cardiol; 1998 Feb; 81(4):424-31. PubMed ID: 9485131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
    García de Vinuesa S; Luño J; Gómez-Campderá F; Ridao N; Sánchez M; Dall'Anese C; Valderrábano F
    Nephrol Dial Transplant; 2001; 16 Suppl 1():78-81. PubMed ID: 11369828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness.
    Zanchetti A; Rosei EA; Dal Palù C; Leonetti G; Magnani B; Pessina A
    J Hypertens; 1998 Nov; 16(11):1667-76. PubMed ID: 9856368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of the antihypertensive effect of verapamil and atenolol.
    Escudero J; Hernandez H; Martinez F
    Am J Cardiol; 1986 Feb; 57(7):54D-58D. PubMed ID: 3513515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
    Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
    J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of verapamil on reinfarction and cardiovascular events in patients with arterial hypertension included in the Danish Verapamil Infarction Trial II. The Danish Study Group on Verapamil in Myocardial Infarction.
    Jespersen CM; Hansen JF
    J Hum Hypertens; 1994 Feb; 8(2):85-8. PubMed ID: 8207744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
    Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group.
    Philipp T; Anlauf M; Distler A; Holzgreve H; Michaelis J; Wellek S
    BMJ; 1997 Jul; 315(7101):154-9. PubMed ID: 9251545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of COER-verapamil on circadian pattern of forearm vascular resistance and blood pressure.
    Nguyen BN; Parker RB; Noujedehi M; Sullivan JM; Johnson JA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1480-7. PubMed ID: 11185670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
    Weber MA; Julius S; Kjeldsen SE; Jia Y; Brunner HR; Zappe DH; Hua TA; McInnes GT; Schork A; Mancia G; Zanchetti A
    J Hypertens; 2012 Nov; 30(11):2213-22. PubMed ID: 23011525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators.
    Rosei EA; Dal Palù C; Leonetti G; Magnani B; Pessina A; Zanchetti A
    J Hypertens; 1997 Nov; 15(11):1337-44. PubMed ID: 9383184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
    JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
    Bakris GL; Gaxiola E; Messerli FH; Mancia G; Erdine S; Cooper-DeHoff R; Pepine CJ;
    Hypertension; 2004 Nov; 44(5):637-42. PubMed ID: 15381674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.